C4X Discovery Holdings plc
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From C4X Discovery Holdings plc
C4XD Inks Third Major Deal, This Time With AZ For Oral COPD Drug
The UK firm has out-licensed its NRF2 activator programme to AstraZeneca in its third major deal of the year as it works to stabilize cash flow through a broad-ranging approach to partnerships.
Dice Thinks It Holds An Ace With Oral IL-17 Inhibitor In Psoriasis
The company believes it has a potential best-in-class oral drug for psoriasis in development following positive first-in-human clinical trial data. A larger Phase II study is needed.
Rising Leaders Class Of 2020: Where Are They Now?
In 2020, In Vivo launched its annual Rising Leaders list to spotlight talent across the life sciences industry. The editorial team selected 30 individuals from across the biopharma, medtech, academic and healthtech sectors. Here we revisit the class of 2020 and see where they are now.
Scrip Asks...What Does 2022 Hold For Biopharma? Part 1: Markets, Competition And Business Strategy
Biopharma industry leaders highlight key concerns and opportunities across production, supply chain and commercial operations. Business transformation is top of mind for many, perhaps unsurprisingly following two years of rapid and mostly successful adaptation to the strictures of the COVID-19 pandemic.
- Drug Discovery Tools
- Other Names / Subsidiaries
- C4X Discovery Limited
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.